Press release 2015-04-24

C-RAD validates its respiratory gating interface for IBA proton and particle therapy

C-RAD has successfully validated the interface for its Catalyst™ product line, which controls the radiation beam for proton and particle treatment systems. The IBA gating interface validation was performed at Westdeutsches Protonentherapiezentrum Essen, in Germany.

With the implementation of this interface C-RAD is now able to also offer the Catalyst to clinics that use an IBA proton therapy system. The validation confirmed the compatibility of IBA's UBTI interface for respiratory gated treatments in proton therapy.

The release includes a generic layer of hardware and software that allows C-RAD to adapt the current implementation to interfaces of other proton and particle therapy vendors with minimal effort. An individual validation is required for each vendor.

The respiratory gating interface for photon therapy is already in clinical use together with Varian and Elekta linear accelerators. The implementation for the Varian TrueBeam is under way.

The Catalyst and Sentinel systems offer the technology required to perform high-end treatment techniques within radiation therapy. With this solution C-RAD supports the whole 4D treatment chain from imaging to delivery. Respiratory gated treatments are frequently used for special cases in which the tumor position changes throughout the respiratory cycle.

"The excellent cooperation with the IBA team on and off site, as well as the support of the clinical team in Essen allowed a seamless validation," says Tim Thurn, CEO of C-RAD. "For C-RAD it is an important step towards positioning the Catalyst system within the fast-growing market of proton and particle therapy. I am glad to be able to announce the successful validation of the UBTI interface. We are working on several projects in the proton therapy market where the gating interface is an important requirement for our customer."

'

About C-RAD

C-RAD develops innovative solutions for use in advanced radiation therapy. The C-RAD group offers products and solutions for patient positioning, tumor localization and radiation treatment systems. End users are radiation therapy clinics worldwide. All product development is conducted in three fully owned subsidiaries: C-RAD Positioning AB, C-RAD Imaging AB and C-RAD Innovation AB, all of which are located in Uppsala, Sweden. Employees currently number 32. C-RAD's business originates from research and development at Karolinska Institutet in Solna, Sweden. Sales of the company's first product, the C-RAD Sentinel™, started in 2007. Cooperation agreements have been signed with Elekta (Sweden), Varian (USA) and IBA (Belgium). C-RAD is represented by distributors specialized in radiation therapy on major markets. C-RAD has established three companies for direct sales: C-RAD Inc. in the US, C-RAD GmbH in Germany and C-RAD WOFE in

China. C-RAD holds 29% of the shares in laser company Cyrpa with an option to acquire the remaining 71%. C-RAD AB is listed on NASDAQ Stockholm.
For more information on C-RAD, please visit www.c-rad.com.

For further information:
Tim Thurn, CEO C-RAD AB, Phone +46-18-666930, Email investors@c-rad.com

The above information is price-sensitive and must therefore be disclosed under the Securities Market Act (2007:528).